P

Pfizer

Makes cancer drugs, vaccines and other medicines

Field Adoption & Experience Lead Senior Manager

Full-TimeUpdated on 10/22/2026Deadline 10/29/26
$111.9k - $207.4k/yr+ 17.5% bonus target + Share-based long-term incentive program
Expert
Collegeville, PA, USA+3 moreMore locations: Lake Forest, IL, USA | Tampa, FL, USA | New York, NY, USA
HybridFlexible schedule; about 2.5 days per week in the office. No change to current work location.
TrainingCorporate & Technical Training, Instructional Design & Curriculum Development
No H1B Sponsorship

About the job

Requirements
  • The candidate must be a current Pfizer field-based colleague or field leader in good standing, with endorsement from their home manager.
  • The candidate must have deep working knowledge of field operations, including territory planning, customer engagement, and field leadership structures.
  • The candidate must demonstrate use of artificial intelligence as a first approach or a clear appetite to build that skill quickly.
  • The candidate must have experience coaching, training, or influencing peers, or leading field initiatives, projects, or pilots.
  • The candidate must have strong communication and stakeholder skills and be able to influence without direct authority.
  • The candidate must be able to manage multiple priorities in a fast-paced, matrixed environment.
Responsibilities
  • Own the change and adoption plan for Scout and other AI-led initiatives affecting field roles, aligned to the enterprise AI Adoption framework led by the Change Deployment & Adoption Lead.
  • Develop communication plans that explain to field colleagues and leaders how AI-led changes affect territory planning, customer engagement, call preparation and follow-up, and ways of working.
  • Tailor the AI Adoption framework to field rhythms, compliance considerations, and the realities of time in territory.
  • Equip field leaders at national, regional, and district levels with activation materials and talking points to champion Scout with their teams.
  • Identify adoption barriers and communication issues early, and manage them to resolution.
  • Feed field signals and lessons learned back to the Change Deployment & Adoption Lead to strengthen enterprise strategy.
  • Build trusted relationships with field leadership, field operations and training leads, and BU Leads to understand readiness, concerns, and priorities.
  • Work with the Scout product owner and AI product teams so activation aligns with product capabilities, roadmap timing, and launch readiness.
  • Support the AIA Joint Product SteerCo with field adoption data and user feedback.
  • Partner with the Commercial AIA Lead and BU Leads to gather ongoing field feedback and channel it back to product teams.
  • Identify and support field champions who can sustain momentum after the secondment ends.
  • Represent field needs in cross-functional forums, including compliance requirements and the customer interaction experience.
  • Maintain the end-to-end plan for Scout activation and other in-scope field initiatives, covering milestones, owners, dependencies, and success criteria.
  • Track delivery against schedule and escalate risks early with proposed mitigations.
  • Coordinate with other Adoption & Experience Leads (Marketing, GAV/Tier 2, Content) to sequence requests and avoid overloading the field.
  • Plan around field calendars, including national meetings, launch cycles, and quarter-end.
  • Design and deliver training for Scout tailored to field roles, including e-learning, live sessions, job aids, quick reference guides, short videos, and FAQs designed for use between customer interactions.
  • Work with field training and field leadership to embed Scout enablement into existing rhythms, such as national and regional meetings, coaching conversations, and new-hire onboarding.
  • Set up a training content lifecycle, including version control and refresh triggers tied to product releases, so materials can be maintained after the secondment.
  • Coordinate training delivery across teams and geographies while respecting time in territory.
  • Direct vendor or staff-augmentation support contributing to field training.
  • Define and track field adoption and training-effectiveness metrics, such as activation rates, weekly usage, usage by role and region, training completion, post-training adoption lift, manager coaching engagement, productivity impact, and satisfaction.
  • Use data and field feedback to refine content, adjust deployment, and improve the user experience.
  • Turn insights into clear recommendations that show business impact.
  • Report progress, risks, and insights to the Change Deployment & Adoption Lead on a regular cadence.
  • Capture lessons learned from each launch and share them with the wider team.
  • Maintain a living handover record throughout the secondment, covering plans, stakeholder maps, open risks, training assets, and metrics.
  • Complete a structured handover to the team in the final weeks, including a walkthrough of priorities and next steps.
  • Share field insights and recommendations with the AIA team and field leadership at the close of the secondment.
  • Support the return to the home role through a reintegration conversation covering skills gained and how to apply them.
Desired Qualifications
  • Experience in field training, field operations, or field leadership roles.
  • Exposure to change management, adoption, or training design; formal certification such as Prosci ADKAR is a plus but not expected.
  • Familiarity with CRM and field enablement platforms, generative AI tools, and learning management system platforms such as Workday Learning.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.